Notably, oncogenic mutations in Hras, Kras, and Nras, are common in approximately 25% of human cancers, and Kras mutations have been identified in 86% of Ras-driven cancers, including about 98% of pancreatic and 53% of colorectal cancers44. The gene discussed is NRAS; the disease is cancer.